Incorporating New Diabetes Treatments: Rx for Therapeutic Inertia

This two part educational series is meant to build clinician knowledge and competence about the best practice for managing Type II Diabetes as related to prescribing non-insulin as well as insulin therapies. These utility driven modules are designed to provide tips and algorithms that the primary care clinician can use in the clinic right away. These modules have been developed as part of the BMC Portfolio Program's Performance Improvement CME activity on Diabetes Management, but has been made available as a public resource.

Part 1 - Non-insulin Therapies

Part 2 - Insulin

Part 1 - Using Non-insulin Agents

At the completion of this module the learner will be able to:

1. Identify the 12 classes of diabetes medications

2. Explain how non-insulin agents address the main pathophysiologic defects of T2DM

3. Recognize the benefits and risks of the newer non-insulin agents for T2DM: DPP-4 inhibitors, GLP-1 RAs and SGLT-2 inhibitors

4. Apply knowledge of metabolic staging of T2DM to initiate and advance therapy, particularly with the newer non-insulin agents

Part 2 - Using Insulin

At the completion of this module the learner will be able to:

1. List circumstances when insulin should be started in T2DM

2. Recognize the action profiles and dosing strategies of commonly used insulins

3. Initiate and advance insulin therapy in T2DM

4. Comfortably practice the combined use of basal and prandial insulins

Date of original release: June 20, 2016
Date of expiration: June 20, 2018

Privacy Policy
BUCME privacy policy:

Target Audience
Physicians, PAs and advance practice nurses in primary care.